What quality-of-life issues do women with ductal carcinoma in situ (DCIS) consider important when making treatment decisions?
- 28 February 2017
- journal article
- research article
- Published by Springer Nature in Breast Cancer
- Vol. 24 (5) , 720-729
Abstract
Purpose To explore quality-of-life (QOL) issues considered important when deciding on treatment for ductal carcinoma in situ (DCIS). Methods Breast Cancer Network of Australia members diagnosed with DCIS in the past 5 years (self-identified) participated in an online survey (Sep–Nov 2015). From a list of 74 QOL issues, participants selected all issues they experienced during DCIS diagnosis, treatment or recovery, then the issues they felt important to making a DCIS treatment decision, and completed the Health Literacy Questionnaire (HLQ). Associations between QOL issues and self-reported treatment received were assessed with χ 2 tests. Results The primary analysis included 38 participants treated with breast-conserving surgery (n = 15), mastectomy (n = 23), and/or radiotherapy (n = 14). Fatigue-related symptoms (82%) and “fear of progression” (50%) were the most frequently-experienced issues. When deciding on DCIS treatment, the most important consideration was “fear of progression” (50%). A higher proportion of mastectomy (compared to non-mastectomy) patients considered “difficultly looking at yourself naked” (p = 0.03). Radiotherapy (compared to non-radiotherapy) patients were more likely to consider “feeling unwell” important (p = 0.006). Results were similar in a sensitivity analysis involving all 101 respondents (i.e., including 63 respondents who reported receiving chemotherapy, endocrine therapy, and/or Herceptin, suggesting that they may have been treated for invasive breast cancer). Health literacy was high across all nine HLQ scales. Conclusion Fear of progression is a key consideration in DCIS treatment decision making for women with high health literacy. QOL treatment considerations differed by treatments received. Women diagnosed with DCIS may benefit from evidence about QOL to inform treatment decision making.Keywords
Funding Information
- Medibank Health Research Fund (n/a)
This publication has 20 references indexed in Scilit:
- Ductal Carcinoma In Situ: A Rose by Any Other NameJNCI: Journal of the National Cancer Institute, 2013
- The grounded psychometric development and initial validation of the Health Literacy Questionnaire (HLQ)BMC Public Health, 2013
- Clinical significance of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 gene polymorphisms in patients with gastrointestinal stromal tumorsAsia-Pacific Journal of Clinical Oncology, 2013
- The early development phases of a European Organisation for Research and Treatment of Cancer (EORTC) module to assess patient reported outcomes (PROs) in women undergoing breast reconstructionEuropean Journal of Cancer, 2013
- Management of ductal carcinoma in situ according to Van Nuys Prognostic Index in Australia and New ZealandAnz Journal of Surgery, 2012
- Ductal Carcinoma In Situ (DCIS): Raising Signposts on an Ill-Marked Treatment PathJNCI: Journal of the National Cancer Institute, 2012
- The challenge of being diagnosed and treated for ductal carcinoma in situ (DCIS)European Journal of Oncology Nursing, 2008
- NATIONAL BREAST CANCER AUDIT: DUCTAL CARCINOMA IN SITU MANAGEMENT IN AUSTRALIA AND NEW ZEALANDAnz Journal of Surgery, 2007
- ‘Well, have I got cancer or haven't I?’ The psycho‐social issues for women diagnosed with ductal carcinoma in situHealth Expectations, 2002
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI: Journal of the National Cancer Institute, 1993